OncoMatch/Clinical Trials/NCT05245500
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Is NCT05245500 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MRTX1719 for mesothelioma.
Treatment: MRTX1719 — This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Small Cell Lung Cancer
Tumor Agnostic
Pancreatic Cancer
Biomarker criteria
Required: MTAP homozygous deletion
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
Cannot have received: MAT2A inhibitor
Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
Lab requirements
Blood counts
Adequate organ function.
Kidney function
Adequate organ function.
Liver function
Adequate organ function.
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Phoenix, Arizona
- Sarah Cannon Research Institute (SCRI) - HealthONE Location · Denver, Colorado
- Rocky Mountain Cancer Centers, LLP - Oncology · Lone Tree, Colorado
- Mayo Clinic · Jacksonville, Florida
- Sarah Cannon Research Institute at Florida Cancer Specialists · Orlando, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify